1999
DOI: 10.1023/a:1018997520950
|View full text |Cite
|
Sign up to set email alerts
|

Untitled

Abstract: The FDA recently issued a guidance covering practices of scaleup and post approval changes with semisolids (SUPAC-SS). This guidance outlines the steps that must be taken by a company to maintain certification of its semisolid dermatological products after quantitative changes have been made in their compositions and/or after changes have been made in the sourcing of their key ingredients, in their processing, in their batch sizes, and/or after their site of manufacture has been relocated. A key element within… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
10
0

Year Published

2004
2004
2019
2019

Publication Types

Select...
8
1
1

Relationship

2
8

Authors

Journals

citations
Cited by 70 publications
(10 citation statements)
references
References 25 publications
0
10
0
Order By: Relevance
“…The DEX flux was calculated from the slope of the linear portion of the curve by plotting the amount of DEX released per cm 2 against the square root of time [38,39]. Results are presented in Figure 9.…”
Section: Resultsmentioning
confidence: 99%
“…The DEX flux was calculated from the slope of the linear portion of the curve by plotting the amount of DEX released per cm 2 against the square root of time [38,39]. Results are presented in Figure 9.…”
Section: Resultsmentioning
confidence: 99%
“…Although in vitro diffusion cell testing generally cannot be used to predict bioavailability in vivo , it is a useful technique for the characterization of drug delivery systems and for product quality control in manufacturing 24,25 . In the present in vitro drug delivery testing, as predicted from diffusion theory in the model simulations, the diffusion coefficients of the drug in the formulations and the diffusion areas for drug release can significantly affect drug release from the formulations, and hence resulting in the different drug release profiles observed among the different formulations and between the conventional and modified diffusion cells.…”
Section: Discussionmentioning
confidence: 99%
“…Various dimensions are described with orifice diameter, receptor volume, and donor chamber size being the most critical to understand to keep variability as low as possible. During the last 20 years, various publications have reviewed various aspects and applications of IVRT as a tool to support topical product development, from scale-up and post-approval changes for non-sterile semisolid dosage forms (SUPAC-SS) to the more recently proposed topical drug classification system (TCS) (5)(6)(7)(8)(9).…”
mentioning
confidence: 99%